Case report

Multidrug-resistant tuberculosis (MDR-TB) and multidrug-resistant HIV (MDR-HIV) syndemic: challenges in resource limited setting

Christian Francisco,1 Mary Ann Lansang,1 Edsel Maurice Salvana,1 Katerina Leyritana2

SUMMARY
Tuberculosis (TB) is common among persons living with HIV. This public health concern is aggravated by infection with multidrug-resistant organisms and adverse effects of polypharmacy. There are few published cases of multidrug-resistant tuberculosis (MDR-TB) in multidrug-resistant HIV (MDR-HIV) infected patients. We report a case of a 29-year-old Filipino man with HIV on zidovudine (AZT)-containing antiretroviral therapy (ART) but was eventually shifted to tenofovir due to anaemia. He presented with left flank tenderness, which was found to be due to an MDR-TB psoas abscess, and for which second-line anti-TB treatment was started. HIV genotyping showed MDR-HIV infection susceptible only to AZT, protease inhibitors and integrase inhibitors. Subsequently, he developed neck abscesses that grew Mycobacterium avium complex and was treated with ethambutol and azithromycin. ART regimen was revised to AZT plus lamivudine and lopinavir/ritonavir. Erythropoietin was administered for recurrent AZT-induced anaemia. Both abscesses resolved and no recurrence of anaemia was noted.

BACKGROUND
The tuberculosis (TB) and HIV coinfection is a global syndemic that increases morbidity and mortality from both diseases. It jeopardises disease control efforts, especially in developing countries like the Philippines. Complicating the scenario is the emergence of drug resistance in both disease entities. Despite the advent of new diagnostic tests to detect resistance, there have been only few published cases of multidrug-resistant tuberculosis (MDR-TB) and multidrug-resistant HIV (MDR-HIV) coinfection. Additional challenges faced are infection with other non-tuberculous mycobacteria (NTM) and unavailability of other classes of antiretroviral therapy (ART) drugs in resource-limited settings. Triple coinfection (TB, HIV, NTM) complicates clinical management with regard to antmycobacterial and ART choices, adverse drug events and compliance issues. We report a complicated case of multiple coinfections and the dilemmas encountered in the course of management.

CASE PRESENTATION
A 29-year-old Filipino man with HIV presented with fever and left flank tenderness. He was diagnosed with HIV infection 1 year prior to his symptoms with a baseline CD4 count of 246 cells/mm³. Workup for active TB which included chest radiographs, direct sputum smear microscopy for acid-fast bacilli (AFB) and sputum GeneXpert MTB/Rif were all negative. Tuberculin skin test (TST) to screen for latent TB infection (LTBI) was not done. We started him on isoniazid preventive therapy (IPT), consisting of isoniazid 300 mg tablet once per day for 6 months. On diagnosis, we started him on an ART regimen consisting of lamivudine (3TC), zidovudine (AZT) and nevirapine (NVP). Baseline HIV genotyping test is not routinely performed in our setting. Baseline and repeat HIV RNA viral load tests were not done due to cost. Six months after ART initiation, he developed AZT-induced anaemia. We discontinued AZT and shifted to tenofovir (TDF).

One year after HIV diagnosis, the patient experienced persistent low back pain with radiation to the left flank area, associated with high-grade fevers. A working diagnosis of a psoas abscess was made. He had no previous history and treatment for TB and other opportunistic infections. He was subsequently admitted for further workup.

INVESTIGATIONS
On admission, ultrasound revealed a fluid collection in the left psoas area. Whole abdominal CT scan confirmed the diagnosis, showing a left paravertebral hypodense collection in the left psoas muscle, consistent with abscess formation (figure 1). A CT-guided aspiration biopsy was done. Microbiological workup of the abscess fluid showed no organism on Gram stain but showed AFB on Ziehl-Neelsen stain. Xpert MTB/Rif detected Mycobacterium tuberculosis (MTB) with rifampicin resistance. Routine bacterial culture did not grow any organisms. Mycobacterial culture (BACTEC 460 TB system, Beckton Dickinson, Maryland, USA) with drug-susceptibility testing (DST) eventually grew MTB, resistant to all first-line anti-TB drugs (including rifampicin, isoniazid, pyrazinamide, ethambutol and streptomycin).

Six months after the TB diagnosis, he developed a left lateral neck mass. Ultrasound revealed an ill-defined hypoechoic focus measuring 4.6×5.5×4.8 ximate volume with an approximate volume of 83 mL. CT scan confirmed the neck abscess (figure 2). Aspiration was done. Gram stain showed...
Despite the adverse effects from antimycobacterial medications and ART, the patient was able to complete treatment for M. avium neck abscess with azithromycin 500 mg tablet every other day and ethambutol 400 mg tablet, 2 tablets per day, for 1 year.

Based on the patient’s HIV genotyping test, the virus was resistant to all NNRTIs and NRTIs except AZT and remained susceptible to all PIs and INSTIs. However, due to the unavailability of INSTIs in our setting, we shifted back ART to 3TC-AZT-based regimen and the addition of ritonavir-boosted lopinavir (LPV/r). After a few months on the new ART regimen, AZT-induced anaemia ensued, necessitating repeated blood transfusions. We then provided the patient with ferrous sulfate 325 mg tablet once per day and erythropoietin (EPO) alpha 4000 units subcutaneously given two times per day to prevent anaemia recurrence.

OUTCOME AND FOLLOW-UP

Despite the adverse effects from antimycobacterial medications and ART, the patient was able to complete treatment for M. avium for 12 months and MDR-TB treatment for 24 months. Neck and abdominal CT scan after treatment revealed resolution of the abscesses. There was no recurrence of anaemia while on EPO and ferrous sulfate. His most recent CD4 count was 778 cells/mm$^3$ and HIV viral load was 192 copies/mL.

DISCUSSION

TB-HIV coinfection is a public health threat. Prevalence of MDR-TB among HIV-infected individuals is highly variable, ranging from 0.6% to 76%, and this coinfection is associated with higher mortality and morbidity. However, very few have reported on the outcomes of patients with MDR-TB and MDR-HIV coinfection. This patient is one of a handful of documented cases of MDR-TB and HIV coinfection, and its management revealed some therapeutic challenges.

Current guidelines recommend that ART be started in all persons living with HIV (PLHIV) regardless of CD4 count. However, ART can cause a range of adverse reactions that may be acute and life-threatening or chronic and insidious. Our patient developed AZT-induced anaemia a few months after starting ART. This occurs in 14.6% of patients on AZT-containing regimen. Management includes shifting to another NRTI, such as TDF. Anaemia usually resolves within 2 weeks after discontinuation of AZT.

HIV infection is the leading risk factor for the progression of LTB1 to active disease. Initiation of IPT is recommended after ruling out active TB. In our patient, active TB was ruled out after an unremarkable chest radiograph, negative bacteriological tests for TB and absence of constitutional symptoms. A meta-analysis has shown that the absence of cough, weight loss, fever and night sweats has a negative predictive value of 98% against the diagnosis of active TB. TST is not required for initiating IPT among PLHIV as recommended by WHO. It is also important to note that NTM infections and previous bacillus Calmette-Guérin vaccination may cause false-positive TST among the...
HIV-infected population but this should not prevent IPT initiation. In addition, the sensitivity of TST for detecting LTBI is reduced for PLHIV. Despite the recommendations to use a lower cut-off values for positive TST result for PLHIV (5 mm diameter instead of 10 mm diameter induration), interpretation of the TST remains to be difficult since skin testnergy is common among PLHIV and is associated with low CD4 count.

Fever in PLHIV is associated with an extensive list of infectious and non-infectious aetiologies. In settings where TB-HIV coinfection is common, TB should always be considered and prompt workup should be instituted. In this case report, our patient presented with an indolent fever, constitutional symptoms and low back pain, which was caused by a tuberculous psoas abscess. TB psoas abscess formation is not unusual among PLHIV. Its management involves aspiration of the abscess and starting appropriate anti-TB drugs. In our case, second-line TB drugs were initiated due to the presence of AFB in the abscess fluid, positive Xpert MTB/Rif (MTB detected/rifampicin resistance detected), and DST. Some studies have shown that the presence of rifampicin resistance is a marker of MDR-TB in areas with high burden of infection. However, Xpert MTB/Rif may not be an optimal stand-alone test for the diagnosis of extrapulmonary TB and should be interpreted with caution. Mycobacterial culture with DST should be included in the workup of an HIV-infected patient suspected to have TB for the following reasons: higher prevalence of MDR-TB among HIV-infected, NTM coinfections, and serves as guidance in the targeted management of MDR-TB.

NTM infection, particularly Mycobacterium avium complex (MAC), is seen in 2% of HIV-infected patients, especially among those with CD4 count <500 cells/mm³. Various case reports have discussed MTB and NTM coinfection among patients with HIV, and there are even reports of coexisting MTB-NTM in a single abscess site such as the brain and lymph nodes. Treatment of NTM is commonly empiric since most of the existing drugs were not specifically developed for the treatment of NTM. Drug activities are usually extrapolated from MTB treatment. Azithromycin and ethambutan were added to this patient’s MTB treatment regimen to cover for MAC. Randomised controlled trials have shown efficacy of azalides (azithromycin or clarithromycin) combined with ethambutan in treating disseminated MAC. Susceptibility studies have shown that azithromycin and ethambutan remain a good option for MAC treatment. However, it is still recommended that drug susceptibility test be performed for all known NTM isolates.

Drug-resistance testing (DRT) through HIV genotyping detects clinically significant mutations in the HIV genome, and is a useful tool for assessing resistance among the commonly used ART drugs, particularly NRTIs and NNRTIs. The downward trend in our patient’s CD4 count and the occurrence of opportunistic infections raised the suspicion of possible resistance. Although not routinely done in resource-limited settings, HIV viral load and (if not suppressed) genotyping is recommended in a patient on ARTs who develops new opportunistic infections, a protracted infection course despite appropriate treatment, or recurrence of a previously resolved infection. However, the utilisation of this test on a larger scale is limited by its availability, accessibility and relatively high cost in resource-constrained settings. Underutilisation of DRT may lead to inadequate investigation of HIV resistance and under-reporting of cases. This may be the reason behind the dearth of published cases of MDR-TB/MDR-HIV coinfection.

The greatest challenge in the management of this case was weighing the HIV genotyping result against the risk of recurrence of a documented adverse drug reaction. In our setting, ART is currently limited to NRTI (3TC, AZT), NNRTI (EFV, NVP) and PI (LPV/r). The current Philippine HIV epidemic is driven by the predominance of the CRF01 AE subtype in contrast to the predominance of subtype B in the Americas, Western Europe and Australasia, and subtype C in Africa. Infection with CRF01 AE has been associated with rapid progression to AIDS and possibly higher mortality, thus ART classes that rapidly suppress HIV viral load are essential. INSTIs comprise a key drug class that has been shown in randomised controlled trials to be more effective in rapidly decreasing HIV viral load within 12 weeks when compared with the standard NNRTI and NRTI combinations, and this effect is similar across most INSTIs. Reports have shown an increasing numbers of pretreatment NNRTI resistance among ART-naïve patients and can be >25% among those experiencing ART failure. In our case, HIV genotyping revealed mutations in K103E and Y181C, causing resistance to EFV and Y181I/V mutations causing resistance to NVP, etravirine and rilpivirine. These transmitted drug resistance (TDR) patterns were reported to occur in 2.2% in a patient cohort in Malawi. On the other hand, NRTI mutations are less prevalent, ranging from 1.6% to 4% among ART-experienced and ART-naïve, respectively. In the Philippines, overall HIV-1 TDR by conventional Sanger-based sequencing is 9.7% overall (NNRTI: 6.2%, NRTI: 1.8% and PI: 2.7%) and was even higher on next-generation sequencing at 5% minority variant cut-off (19.5% overall, NNRTI: 13.3%, NRTI: 2.7%, PI: 4.4%, INSTI 1.8%). In our case, the patient had M184V & M230L mutations conferring resistance to 3TC, emricitabine (FTC), didanosine (ddI) and abacavir (ABC), while K65R causes intermediate to high-level phenotypic and clinical resistance to TDF, ddI, ABC and d4T and low level to intermediate phenotypic and
clinical resistance to 3TC and FTC. Drug resistance surveillance of CRF01_AE subtype in a Chinese cohort experiencing ART failure reported occurrence of M184V and K65R mutations at 64.98% and 15.97%, respectively, among treatment failures. The M184V mutation is not a contraindication to a continued treatment with 3TC or FTC, thus 3TC remained a part of our patient’s ART regimen. Studies have shown that the presence of M184V mutation is not associated with virological failure even if 3TC or FTC were continued, as long as other active drugs are present.

In our setting where new ART classes remain unavailable, there was a risk in resuming AZT, which previously caused profound anaemia in our patient. Weighing the benefit over the risk, control of the HIV infection was paramount, and the anaemia was managed through blood transfusions as needed. AZT-induced anaemia is postulated to occur due to low levels of endogenous EPO, unresponsiveness to the usual endogenous concentrations, or compounded by HIV infection. EPO administration in patients with AZT-induced anaemia has been showed to improve mean haematocrit levels and decrease frequency of blood transfusions. Pls remain the preferred second-line ART in resource limited setting. Baseline DRT should be routinely performed as NNRTI resistance increases, and if not done, Pls should be considered as part of the initial ART regimen due to its high genetic barrier for resistance. However, Pls are associated with metabolic complications including dyslipidemia, hyperglycemia and lipodystrophy. INSTIs may be a better option since they are potent, well tolerated and have less adverse effects.

Acknowledgements The authors would like to thank their colleagues Dr Marie Joyce Santos, Dr Maria Jonelyn Colobong, and the clinic staff of SAGIP Unit of the Philippine General Hospital and Sustained Health Initiatives of the Philippines.

Contributors CF, MAL and EMS conceived the design of the study, performed data collection and analysis, revised the manuscript and approved the final manuscript. KL performed data collection and analysis, revised the manuscript and approved the final manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES

1. Pepper DJ, Schomaker M, Wilkinson RJ, et al. Independent predictors of tuberculosis mortality in a high HIV prevalence setting: a retrospective cohort study. AIDS Res Ther 2015;6:5.
2. Sattar H, McLoughlin MM, Seung KJ. Drug-resistant tuberculosis treatment complicated by antiretroviral resistance in HIV coinfected patients: a report of six cases in Lesotho. Am J Trop Med Hyg 2013;89:174–7.
3. Hurtado RM, Meressa D, Goldfield AE. Treatment of drug-resistant tuberculosis among people living with HIV. Curr Opin HIV AIDS 2018;13:478–85.
4. Zürcher K, Ballif M, Fennet L, et al. Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries: a multicentre cohort study. Lancet Infect Dis 2019;19:298–307.
5. World Health Organization. Guidance on When to Start Antiretroviral Therapy and On-pre Exposure Prophylaxis for HIV. 2015. http://apps.who.int/iris/bitstream/10665/186275/1/19789241509565_eng.pdf
6. AIDSSirsch. Guidelines for the Use of antiretroviral agents in HIV-1-infected adults and adolescents. http://aidsinfo.nih.gov/guidelines
7. Dash KR, Meher UK, Hui PK, et al. High incidence of zidovudine induced anaemia in HIV infected patients in Southern Odisha. Indian J Hematol Blood Transfus 2015;31:247–50.
8. Max B, Sherer R. Management of the adverse effects of antiretroviral therapy and medication adherence. Clin Infect Dis 2000;30:596–5116.
9. van der Sande MA, Schim van der Loeff MF, Bennett RC, et al. Incidence of tuberculosis and survival after its diagnosis in patients infected with HIV-1 and HIV-2. AIDS 2004;18:18.
10. Getahun H, Kitiraiak W, Heilig CM, et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med 2011;8:e1000391.
11. World Health Organization. Guidelines for intensified case finding and isoniazid prevention therapy for people living with HIV in resource-constrained settings.
12. Centers For Disease Control And Prevention. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from Centers For Disease Control And Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009;58:16.
13. Cobelens FG, Egwegwe SM, van Ginkel T, et al. Tuberculin skin testing in patients with HIV: validity and impact of reduced cut-off values. Clin Infect Dis 2006;43:634–9.
14. Long R, Houston S, Hershfield E, et al. Recommendations for screening and prevention of tuberculosis in patients with HIV and for screening for HIV in patients with tuberculosis and their contacts. CMAJ 2003;169:789–91.
15. Thinh QM, Nguyen HI, Nguyen VN, et al. Tuberculosis and HIV co-infection-focus on the Asia-Pacific region. Int J Infect Dis 2015;32:170–8.
16. Fozatik L, Ballachandran T. Bilateral posas absesses in an HIV-positive patient. Int J STD AIDS 2004;15:841–3.
17. Rakesh TP, Kidangazhiathanma A, Jyothish K, et al. Large Primary Tuberculous Posas Abscess in an HIV Patient – A Case report. SAARC Journal of Tuberculosis, Lung Diseases & HIV/AIDS 2014.
18. Denkinger CM, Pai M, Doody DW, et al. Do we need to detect isoniazid resistance in addition to rifampicin resistance in diagnostic tests for tuberculosis? PLoS One 2014;9:e84197.
19. Karre SS, Sangale SA, Kiyawat DS, et al. Mycobacterium avium-intracellulare brain abscess in HIV-positive patient. Ann Indian Acad Neurology 2012;5:54–5.
20. Isakidop L, Das M, Kumar AM, Ajay M, et al. Alarming levels of drug-resistant tuberculosis in HIV-infected patients in metropolitan Mumbai, India. PLoS One 2019;4:e110461.
21. McCarthy KD, Cain KP, Winthrop KL, et al. Nontuberculous mycobacterial disease in patients with HIV in Southeast Asia. Am J Respir Crit Care Med 2012;185:981–8.
22. Nyamogoba HD, Mbutia G, Minting S, et al. HIV co-infection with tuberculosis and non-tuberculous mycobacteria in western Kenya: challenges in the diagnosis and management. Afr Health Sci 2012;12:305–11.
23. Sharma K, Mewara A, Gupta N, et al. Multiplex PCR in diagnosis of M. tuberculosis and M. avium co-infection from lymph node in an AIDS patient. Indian J Med Microbiol 2015;33:151–3.
24. Egelund EF, Fennelly KP, Pelouquin CA. Medications and monitoring in nontuberculous mycobacterias infections. Clin Chest Med 2015;36:55–66.
25. Durnne M, Fessell J, Kumar P, et al. A randomized, double-blind trial comparing azithromycin and clarithromycin in the treatment of disseminated Mycobacterium avium infection in patients with human immunodeficiency virus. Clin Infect Dis 2000;31:1245–52.
26. Ward TT, Rimland D, Kaufman C, et al. Randomized, open-label trial of azithromycin plus ethambutol vs. clarithromycin plus ethambutol as therapy for Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection. Veterans Affairs HIV Research Consortium. Clin Infect Dis 1998;27:1278–85.
27. Heidelberg J, Minaei M, Hashemzadeh M, et al. In vitro antimicrobial susceptibility of nontuberculous mycobacteria in Iran. Microb Drug Resist 2016;22:172–8.
28. Van den Eede P, Van Wesenbeeck L, Verlinden Y, et al. HIV-1 genotyping of the protease-reverse transcriptase and integrase genes to detect mutations that confer antiretrovirial resistance. Methods Mol Biol 2013;1050:37–55.
29. Salaffa EMT, Schwem BE, Ching PR, et al. The changing molecular epidemiology of HIV in the Philippines. Int J Infect Dis 2017;61:44–50.
30. Chen Y, Hora B, DeMarco T, et al. Increased predominance of HIV-1 CRF01_AE and its recombinants in the Philippines. J Gen Virol 2019;100:511–22.
31. Taylor BS, Sobieszczak ME, McCutchan FE, et al. The challenge of HIV-1 subtype diversity. N Engl J Med 2008;358:1590–602.
32. Costello C, Nelson KE, Suliyanon V, et al. HIV-1 subtype E progression among northern Thai couples: traditional and non-traditional predictors of survival. Int J Epidemiol 2005;34:577–84.
33. Kitto C, Szubert AJ, Silka A, et al. Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial, PLoS Med 2015;12:1–20.
34. Raffi F, Raffels A, Steillink HU, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 2013;383:735–43.
35. Rutstein SE, Chen JS, Nelson JAE, et al. High rates of transmitted NNRTI resistance among persons with acute HIV infection in Malawi: implications for first-line dolutegravir scale-up. AIDS Res Ther 2019;16:5.
36 Karade S, Sen S, Sashindran VK, et al. Absence of Integrase Strand Transfer Inhibitor Associated Resistance in Antiretroviral Therapy Naïve and Experienced Individuals from Western India. AIDS Res Hum Retroviruses 2019;0:1–10.

37 World Health Organization. HIV drug resistance report. 2017. http://www.who.int/hiv/pub/drugresistance/hivdr-report-2017/en/

38 Dong K, Ye L, Leng Y, et al. Prevalence of HIV-1 drug resistance among patients with antiretroviral therapy failure in Sichuan, China, 2010-2016. Tohoku J Exp Med 2019;247:1–12.

39 Ngo-Giang-Huong N, Huynh THK, Dagnra AY, et al. Prevalence of pretreatment HIV drug resistance in West African and Southeast Asian countries. J Antimicrob Chemother 2019;74:462–7.

40 Salvana EM, Duncia N, Aarevalo G, et al. 1282. Detection of HIV-Transmitted Drug Resistance by Next-Generation Sequencing in a CRF01_AE Predominant Epidemic. Open Forum Infect Dis 2018;5(Suppl 1):S391.

41 Gagliardini R, Ciccillo A, Borghetti A, et al. Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals with Suppressed HIV-1 RNA: A Cohort Study. Open Forum Infect Dis 2018;5:ofy113.

42 Kuehl AK, Noormohamed SE. Recombinant erythropoietin for zidovudine-induced anemia in AIDS. Ann Pharmacother 1995;29(7-8):778–9.

43 Henry DH, Beall GN, Benson CA, et al. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Overview of four clinical trials. Ann Intern Med 1992;117:739–48.

44 Tang MW, Shafer RW. HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs 2012;72:1–e25.

45 Hejazi N, Rajkan R, Choong CL, et al. Metabolic abnormalities in adult HIV infected population on antiretroviral medication in Malaysia: a cross-sectional survey. BMC Public Health 2013;13:758.

46 Raffi F, Esser S, Nunnari G, et al. Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens. HIV Med 2016;17:3–16.